TALS News and Press, Talaris Therapeutics Inc. From 02/16/23

Talaris Therapeutics ( NASDAQ: TALS ) is up 10% in premarket trading after announcing a corporate restructuring and starting a review of strategic alternatives. The cell therapy company is discontinuing two trials examining FCR001 for durable tolerance in living donor kidney trans...

BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) , today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials ...

Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...

BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) , a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood d...

Talaris Therapeutics press release ( NASDAQ: TALS ): Q3 GAAP EPS of -$0.46 misses by $0.05 . Cash, Cash Equivalents and Marketable Securities: Talaris finished the third quarter of 2022 with $193.9 million in cash, cash equivalents, and marketable securities compared w...

Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash balance with expected runway through 2024 BOSTON ...

BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...

H.C. Wainwright has initiated Talaris Therapeutics ( NASDAQ: TALS ) with a buy rating saying that the biotech's allogeneic hematopoietic stem cell (Allo-HSCT) transplantation platform can transform the standard of care in many areas. The firm has a $18 price target (~644% upsi...

Cell therapy company Talaris Therapeutics ( NASDAQ: TALS ) shed ~24% pre-market Thursday after reporting a death in a kidney transplant patient in its Phase 3 trial for lead candidate FCR001. The patient who was initially diagnosed with grade II acute graft-vs-host dis...

BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...